ADC Therapeutics SA reports news on its commercial-stage oncology business focused on antibody-drug conjugates. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC with FDA accelerated approval and European Commission conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Recurring updates cover ZYNLONTA product revenue, manufacturing and commercialization activity, clinical development in combination regimens and earlier lines of therapy, including LOTIS program studies, and corporate financing matters. Company news also includes quarterly financial results, investor presentations, conference participation and equity inducement grants under its compensation plans.
Freenome presented promising research at the ASH Annual Meeting regarding their multiomics platform's ability to identify biomarkers for response to ADC Therapeutics' drug, loncastuximab tesirine (lonca), in treating DLBCL. The collaboration is set to enhance the understanding of treatment efficacy and mechanisms of resistance in patients. Results indicate potential for improved patient-specific predictions using cfDNA profiling combined with clinical data. Both companies emphasize the importance of these findings in guiding treatment strategies for DLBCL patients.
Biocytogen Pharmaceuticals announced an agreement with ADC Therapeutics (NYSE: ADCT) to evaluate Biocytogen's proprietary antibodies against three tumor targets. This agreement allows ADC Therapeutics to license selected antibodies for global development, with Biocytogen retaining all rights beyond ADC development. The agreement includes an upfront payment, option-exercise fees, and milestone payments that may total tens of millions, alongside royalties on net sales. This partnership aims to leverage both companies' expertise in antibody drug conjugates (ADCs) for innovative cancer treatments.
ADC Therapeutics reported strong financial results for Q3 2022, with net sales of $21.3 million for ZYNLONTA, reflecting a 23% increase from Q2 2022. The company has a cash runway extending into early 2025, supported by a $175 million loan and a $55 million upfront payment from a licensing agreement. The LOTIS-5 trial showed favorable initial results, enhancing the outlook for ZYNLONTA. However, the company is pausing significant investments in the Cami program, awaiting further FDA guidance.
ADC Therapeutics (NYSE: ADCT) announced that CEO Ameet Mallik will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15 at 9:45 a.m. GMT. A live webcast will be available on the company's Investors page, with a replay accessible for 30 days. The company specializes in targeted antibody drug conjugates aimed at improving cancer treatment. Its FDA-approved ADC, ZYNLONTA, is used for treating diffuse large B-cell lymphoma, among other ongoing trials.
ADC Therapeutics announced the presentation of multiple abstracts at the 64th American Society of Hematology Annual Meeting in New Orleans from December 10-13, 2022. Highlights include oral presentations on ZYNLONTA (loncastuximab tesirine-lpyl) and ADCT-602, focusing on their efficacy in treating lymphomas. Key presentations involve studies on real-world effectiveness, ongoing Phase 2 trials for Hodgkin lymphoma, and new combinations of ZYNLONTA. Notably, ZYNLONTA has received FDA approval for treating certain B-cell lymphomas, emphasizing its potential in difficult-to-treat cases.
IGM Biosciences and ADC Therapeutics have formed a clinical trial collaboration to examine a combination therapy for relapsed/refractory B cell non-Hodgkin’s lymphoma (NHL). This partnership will evaluate IGM’s imvotamab, a bispecific antibody, alongside ADC’s ZYNLONTA®, an antibody-drug conjugate. The Phase 1 trial is slated to commence in Q1 2023. Previous data indicated a 50% complete response rate for imvotamab at optimal dosing, with manageable safety profiles. Both companies aim to address significant unmet medical needs in lymphoma treatments.
ADC Therapeutics announced the appointments of Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer, effective November 17, 2022, and November 1, 2022, respectively. Harrington-Smith brings over 20 years of experience in pharmaceuticals, having led important product launches in hematological diseases. Graham, with over 25 years in legal management, aims to support ADC's regulatory and commercial strategies. Both leaders will contribute to maximizing the commercial potential of ZYNLONTA, ADC Therapeutics' CD19-directed ADC.
ADC Therapeutics (NYSE: ADCT) will host a conference call on November 8, 2022 at 8:30 a.m. ET to discuss its third quarter 2022 financial results and provide updates.
The call will be accessible via registration, and details will be available on the ADC Therapeutics investor website. The company specializes in antibody drug conjugates (ADCs) for cancer treatment, with its approved product, ZYNLONTA®, currently aiding patients with relapsed or refractory lymphoma.
ADC Therapeutics (NYSE: ADCT) announced positive results from the initial safety run-in of the LOTIS-5 Phase 3 trial, showing a 75% overall response rate and a 40% complete response rate for ZYNLONTA in combination with rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma. The results will be presented at the SOHO 2022 conference in Houston, Texas from September 28-October 1, 2022. Additionally, the company plans to showcase pivotal Phase 2 data for Camidanlumab Tesirine (Cami) during the event.
ADC Therapeutics (NYSE: ADCT) and Swedish Orphan Biovitrum AB announce a positive opinion from the CHMP of the European Medicines Agency, recommending ZYNLONTA® (loncastuximab tesirine) for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This opinion is now under review by the European Commission, with a decision expected in 4Q 2022. Earlier, ADC Therapeutics secured an exclusive licensing deal with Sobi for ZYNLONTA's development in Europe. The favorable CHMP opinion reflects progress towards broader patient access in Europe.